ATUM
20 articles about ATUM
-
ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders
10/4/2023
ATUM today announced an expanded partnership with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases.
-
ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics
1/24/2023
ATUM, a global specialist and industry leader in bioengineering solutions, announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.
-
Wheeler Bio Licenses ATUM's Proprietary Leap-In Transposase® Technology in Support of its Disruptive CDMO Service Offering
11/30/2022
Wheeler Bio, Inc., a contract development and manufacturing organization specializing in the development and manufacturing of mammalian-expressed protein therapeutics, announced it has been granted a license to ATUM's proprietary Leap-In Transposase® and miCHO™ cell line development technology.
-
ATUM Partners with TrioBio to Deliver Leap-In Transposase®-Based Bioengineering Solutions to the Chinese Pharmaceutical Market
4/20/2022
ATUM announced a distribution partnership with Trio Biotech, Co Ltd. to market and promote ATUM’s unique Leap-In Transposase® platform in China.
-
Rentschler Biopharma and ATUM Announce Leap-In Transposase® Licensing Agreement for Development of Robust Manufacturing Processes for Complex Therapeutic Proteins
10/14/2020
License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools
-
ATUM and Phylex BioSciences Collaborate to Accelerate the Development of a Universal SARS Coronavirus Vaccine
6/15/2020
ATUM and Phylex BioSciences have entered into a collaboration to leverage ATUM's Leap-In Transposase® platform to develop the cell line essential to the manufacturing of Phylex's universal SARS coronavirus vaccine candidate.
-
ATUM Provides COVID-19 Diagnostic and Therapeutic Developers Free Access to its Protein Synthesis Platform
3/25/2020
Company’s Leap-In Transposase® platform enables the rapid large-scale production of proteins critical to the development of diagnostics, vaccines and therapeutics
-
ATUM Completes Transition to 100% Renewable Electricity for State-of-the-Art Bioproduction Facility
6/11/2019
ATUM, a Newark, California-based leader in bioengineering and bioproduction, announced the completion of a $1.5 million 26,000 sq. ft solar panel installation at its corporate headquarters and manufacturing site.
-
ATUM Licenses Exclusive Access to Proprietary Gene-Coding Algorithm for Plant-Based Recombinant Protein Expression to Medicago
5/28/2019
ATUM announced the exclusive licensing of gene-coding algorithm GeneGPS® to optimize protein expression in Nicotiana benthamiana to Medicago, a global leader in the development and production of plant-derived vaccines and therapeutic proteins.
-
Solentim and ATUM announce technology collaboration to enable rapid, high expression, stable cell line development
1/14/2019
Solentim, a global leader in Cell Line Development instrumentation, and bioengineering company ATUM, today announced a technology partnering and collaboration agreement.
-
DNA 2.0, Inc. Becomes ATUM
12/12/2016
-
DNA 2.0, Inc. LeapIn Transposons Protected By Newly Issued U.S. Patent
9/1/2016
-
DNA 2.0, Inc. Acquires MIGS To Add Antibody Production Capabilities
4/26/2016
-
Pareto Biotechnologies Announces Technology Partnership With DNA 2.0, Inc.
7/14/2014
-
DNA 2.0, Inc. Partners With Newcastle University on Bacillus Subtillis Expression System
11/28/2012
-
DNA 2.0, Inc. Taps VTU Technology as Research Partner for Industrial Scale Protein Expression
9/18/2012
-
Pfenex Inc. and DNA 2.0, Inc. Collaborate on Protein Expression Technology
3/1/2012
-
DNA 2.0, Inc. Announces Opening of European Office
2/7/2008
-
Operon Biotechnologies, Inc. and DNA 2.0, Inc. Announce Co-Marketing and Technology Development Partnership
8/22/2007
-
Operon Biotechnologies, Inc. and DNA 2.0, Inc. Announce Co-Marketing and Technology Development Partnership
8/22/2007